Stephen Schuster
Impact in
Papers in
-
- Lymphoma Diagnosis and Treatment 204
- Oncology 250
- CAR-T cell therapy research 188
- Viral-associated cancers and disorders 35
- Cancer Immunotherapy and Biomarkers 21
- Co-authors
- Elise A. Chong (79 shared papers)Jakub Svoboda (104 shared papers)Sunita Dwivedy Nasta (106 shared papers)Carl H. June (24 shared papers)Simon Francis Lacey (15 shared papers)Bruce L. Levine (18 shared papers)Daniel Jeffrey Landsburg (62 shared papers)Edward Allen Stadtmauer (51 shared papers)
- Journals
- Blood (113 papers)Blood Advances (30 papers)Hematological Oncology (21 papers)American Journal of Hematology (19 papers)Transplantation and Cellular Therapy (17 papers)
- Partner nations
- United StatesSwitzerlandAustralia
In The Last Decade
Stephen Schuster
408 papers receiving 25.8k citations
Stephen Schuster's Hit Papers
Peers
Comparison fields: 5 of 130
- Oncology 16.5k
- Genetics 6.1k
- Pathology and Forensic Medicine 9.5k
- Immunology 5.5k
- Hematology 2.4k
Countries citing papers authored by Stephen Schuster
This map shows the geographic impact of Stephen Schuster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Schuster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Schuster more than expected).
Fields of papers citing papers by Stephen Schuster
This network shows the impact of papers produced by Stephen Schuster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Schuster. The network helps show where Stephen Schuster may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephen Schuster, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 431 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Hit paper breakdown → | 2018 | 3227 |
| 2 | PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma Hit paper breakdown → | 2014 | 3021 |
| 3 | Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas Hit paper breakdown → | 2017 | 1531 |
| 4 | Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia Hit paper breakdown → | 2014 | 1374 |
| 5 | PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma Hit paper breakdown → | 2014 | 897 |
| 6 | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study Hit paper breakdown → | 2016 | 875 |
| 7 | Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study Hit paper breakdown → | 2021 | 452 |
| 8 | 2016 | 429 | |
| 9 | Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial Hit paper breakdown → | 2021 | 414 |
| 10 | Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma Hit paper breakdown → | 2021 | 393 |
| 11 | Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis Hit paper breakdown → | 2018 | 387 |
| 12 | Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study Hit paper breakdown → | 2021 | 365 |
| 13 | 2003 | 358 | |
| 14 | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study Hit paper breakdown → | 2022 | 343 |
| 15 | An NK-like CAR T cell transition in CAR T cell dysfunction Hit paper breakdown → | 2021 | 309 |
| 16 | 2001 | 305 | |
| 17 | Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy Hit paper breakdown → | 2021 | 261 |
| 18 | 2017 | 259 | |
| 19 | Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy Hit paper breakdown → | 2022 | 258 |
| 20 | 2016 | 235 |
About Stephen Schuster
Stephen Schuster is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Hematology and Immunology, having authored 431 papers that have together received 26.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (204 papers), CAR-T cell therapy research (188 papers), Chronic Lymphocytic Leukemia Research (125 papers), Viral-associated cancers and disorders (35 papers), Integrated Circuits and Semiconductor Failure Analysis (24 papers), CNS Lymphoma Diagnosis and Treatment (24 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Virus-based gene therapy research (21 papers). The work is most often cited by research in Oncology (16.5k citations), Genetics (6.1k citations), Pathology and Forensic Medicine (9.5k citations), Immunology (5.5k citations) and Hematology (2.4k citations). Stephen Schuster has collaborated with scholars based in United States, Switzerland and Australia. Frequent co-authors include Elise A. Chong, Jakub Svoboda, Sunita Dwivedy Nasta, Carl H. June, Simon Francis Lacey, Bruce L. Levine, Daniel Jeffrey Landsburg, Edward Allen Stadtmauer, David L. Porter and Jan Joseph Melenhorst. Their work appears in journals such as Blood, Blood Advances, Hematological Oncology, American Journal of Hematology and Transplantation and Cellular Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.